Smoking, nicotine and Parkinson's disease
- PMID: 15331239
- DOI: 10.1016/j.tins.2004.06.008
Smoking, nicotine and Parkinson's disease
Abstract
Epidemiological studies show that smoking is associated with a lower incidence of Parkinson's disease (PD). This finding is important because it could provide clues about therapeutic strategies for protection against this debilitating movement disorder. Smoke contains numerous chemicals that could be responsible for the apparent protective effect. Here, a role for nicotine is considered, because this chemical stimulates brain dopaminergic systems and provides some symptomatic benefit in PD. Nicotine also has a neuroprotective action. Putative factors and signaling pathways involved in the actions of nicotine are discussed. An understanding of the molecular basis for the reduced occurrence of PD in tobacco users is crucial for the development of intervention strategies to reduce or halt disease progression.
Similar articles
-
Multiple roles for nicotine in Parkinson's disease.Biochem Pharmacol. 2009 Oct 1;78(7):677-85. doi: 10.1016/j.bcp.2009.05.003. Epub 2009 May 9. Biochem Pharmacol. 2009. PMID: 19433069 Free PMC article. Review.
-
Nicotinic receptors as CNS targets for Parkinson's disease.Biochem Pharmacol. 2007 Oct 15;74(8):1224-34. doi: 10.1016/j.bcp.2007.06.015. Epub 2007 Jun 17. Biochem Pharmacol. 2007. PMID: 17631864 Free PMC article. Review.
-
Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development.Neurosci Biobehav Rev. 2007;31(3):287-314. doi: 10.1016/j.neubiorev.2006.09.008. Epub 2006 Dec 4. Neurosci Biobehav Rev. 2007. PMID: 17141870 Review.
-
Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.Trends Pharmacol Sci. 2007 May;28(5):229-35. doi: 10.1016/j.tips.2007.03.001. Epub 2007 Apr 6. Trends Pharmacol Sci. 2007. PMID: 17412429 Review.
-
Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.J Cereb Blood Flow Metab. 2009 Sep;29(9):1601-8. doi: 10.1038/jcbfm.2009.74. Epub 2009 Jun 3. J Cereb Blood Flow Metab. 2009. PMID: 19491921
Cited by
-
The promise of neuroprotective agents in Parkinson's disease.Front Neurol. 2011 Nov 21;2:68. doi: 10.3389/fneur.2011.00068. eCollection 2011. Front Neurol. 2011. PMID: 22125548 Free PMC article.
-
Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.Drug Saf. 2008;31(5):399-407. doi: 10.2165/00002018-200831050-00004. Drug Saf. 2008. PMID: 18422380
-
Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.Curr Protein Pept Sci. 2009 Oct;10(5):483-99. doi: 10.2174/138920309789351921. Curr Protein Pept Sci. 2009. PMID: 19538146 Free PMC article. Review.
-
Targeting nicotinic receptors for Parkinson's disease therapy.CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):651-8. doi: 10.2174/187152711797247849. CNS Neurol Disord Drug Targets. 2011. PMID: 21838678 Free PMC article. Review.
-
Dopamine-dependent modulation of rat globus pallidus excitation by nicotine acetylcholine receptors.Exp Brain Res. 2016 Feb;234(2):605-16. doi: 10.1007/s00221-015-4491-6. Epub 2015 Nov 13. Exp Brain Res. 2016. PMID: 26563165
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
